Cargando…

Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital

INTRODUCTION: Infections are a leading cause of morbidity and mortality in patients with multiple myeloma. The epidemiology, risk factors and outcomes of viral respiratory tract infections (vRTI) are not well described in patients with multiple myeloma managed with novel agents, the current standard...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teh, Benjamin W., Worth, Leon J., Harrison, Simon J., Thursky, Karin A., Slavin, Monica A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087950/ https://www.ncbi.nlm.nih.gov/pubmed/25487843 http://dx.doi.org/10.1007/s00520-014-2550-3

Ejemplares similares

1121. Epidemiology and Risks for Infection Following Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy at an Australian Centre
por: Smibert, Olivia, et al.
Publicado: (2018)

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling
por: Teh, Benjamin W., et al.
Publicado: (2017)

1010. Exploring Antimicrobial Prescriptions in a National Audit of Hematology/Oncology Inpatients Compared with the General Inpatient Population: Targeted Analysis Highlights Key Areas for Targeted Intervention
por: Douglas, Abby, et al.
Publicado: (2019)

Prophylactic Antimicrobial Prescribing in Australian Residential Aged-Care Facilities: Improvement is Required
por: Bennett, Noleen, et al.
Publicado: (2022)

Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing
por: Sim, Starling A., et al.
Publicado: (2018)

The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients
por: Trubiano, Jason A., et al.
Publicado: (2015)

Identifying barriers and enablers to participation in infection surveillance in Australian residential aged care facilities
por: Watson, Eliza, et al.
Publicado: (2023)

Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs
por: Thursky, Karin, et al.
Publicado: (2018)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network
por: Trubiano, Jason A., et al.
Publicado: (2016)

Infection with Scedosporium apiospermum and S. prolificans, Australia
por: Cooley, Louise, et al.
Publicado: (2007)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma
por: Sim, Beatrice Z., et al.
Publicado: (2023)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Using process mapping to identify barriers to effective management of sepsis in a cancer hospital: lessons for successful implementation of a whole hospital pathway
por: Thursky, K, et al.
Publicado: (2014)

Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis
por: Klimas, Rafael, et al.
Publicado: (2021)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era
por: Wei, Min, et al.
Publicado: (2021)

Ophthalmic Antimicrobial Prescribing in Australian Healthcare Facilities
por: Fang, Xin, et al.
Publicado: (2022)

Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting
por: Xie, Ouli, et al.
Publicado: (2020)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria
por: Korubo, Kaladada I., et al.
Publicado: (2017)

An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital
por: Worth, L J, et al.
Publicado: (2005)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era
por: Liu, Siwei, et al.
Publicado: (2019)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1hucqvrdt7ho4hmtuuvfmf1t20